Table 1. Patient biochemical analysis results since the first visit

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Days after visit | 1 | 7 | 13 | 18 | 26 | 40 | 47 | 61 | 75 | 83 | 103 | 131 |
| TARC/CCL17  (pg/mL) | - | - | 10,270 | - | - | - | 10,630 | - | - | 7,046 | 2,962 | 2,122 |
| LDH  (IU/L) | 929 | 621 | 671 | 651 | 737 | 580 | 600 | 497 | 463 | 477 | 471 | 420 |
| KL-6  (U/mL) | 909 | - | 1,003 | 942 | 1,107 | 1,011 | 1,040 | 1,001 | 925 | 935 | 890 | 769 |
| SP-A  (ng/mL) | - | 319 | - | 244 | 493 | 462 | - | 300 | 300 | - | 241 | 209 |
| SP-D  (ng/mL) | - | 2770 | - | 2580 | 3080 | 2220 | - | 1770 | 2000 | - | 1950 | 1000 |

TARC/CCL17, thymus and activation-regulated chemokine/C-C motif chemokine ligand 17; LDH, lactate dehydrogenase; KL-6, Krebs von den Lungen-6; SP-A, surfactant protein A; SP-D, surfactant protein D; -, no data.